There are no items to display.
Acuitas has No Further Rights to Use or Sublicense Arbutus LNP Technology
Arbutus Consolidates LNP Patent Estate Enabling RNAi, mRNA, and Gene-editing Therapeutics
“This settlement terminates Acuitas’ right to use or sublicense our LNP technology going forward, making permanent the effect of the Court’s prior injunction,” said Dr. Mark J Murray, Arbutus President and CEO. “Arbutus LNP represents the most clinically validated delivery technology suitable for RNAi, mRNA therapeutics and gene editing applications. With the settlement of the Acuitas litigation, Arbutus has now consolidated its LNP intellectual property estate. This is a major milestone which establishes Arbutus as the owner and only source of this industry-leading technology platform with the ability to develop a full range of applications.”
The settlement stipulates that the four non-exclusive viral vaccine sublicenses previously granted to Moderna are the only sublicenses to survive. These four sublicenses, previously granted by Acuitas to Moderna under the pre-
Manager, Investor Relations
Source: Arbutus Biopharma Corporation